On-Demand Treatment of Acute Attacks in Hereditary C1 Inhibitor Deficiency

Clinical Scenario

Hereditary C1 inhibitor deficiency causes recurrent angioedema attacks of unpredictable onset and severity. Managing each acute episode promptly is central to care — early intervention has direct consequences for how quickly and completely the attack resolves.

Treatment Goals

Resolution of angioedema symptoms

Shorter total attack duration

Treatment Approach (partial)

The protocol specifies on-demand therapy to be initiated as early as possible at the time of an attack — the agent selection, sequencing, and clinical decision points are detailed in the full structured regimen.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1111/all.15214

We recommend that attacks are treated with either intravenous C1 inhibitor, ecallantide or icatibant.
For HAE-1/2, icatibant, ecallantide and intravenous C1-INH are the recommended on-demand treatments of choice.
We recommend that attacks are treated as early as possible.
Early treatment is associated with a shorter time to resolution of symptoms and shorter total attack duration regardless of attack severity.

View source ↗